Hedley D - Search Results

1

A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas.

Duran I, Kortmansky J, Singh D, Hirte H, Kocha W, Goss G, Le L, Oza A, Nicklee T, Ho J, Birle D, Pond GR, Arboine D, Dancey J, Aviel-Ronen S, Tsao MS, Hedley D, Siu LL. Duran I, et al. Among authors: hedley d. Br J Cancer. 2006 Nov 6;95(9):1148-54. doi: 10.1038/sj.bjc.6603419. Epub 2006 Oct 10. Br J Cancer. 2006. PMID: 17031397 Free PMC article. Clinical Trial.

2

Signaling interactions of rapamycin combined with erlotinib in cervical carcinoma xenografts.

Birle DC, Hedley DW. Birle DC, et al. Mol Cancer Ther. 2006 Oct;5(10):2494-502. doi: 10.1158/1535-7163.MCT-05-0504. Mol Cancer Ther. 2006. PMID: 17041093

3

Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience.

Knox JJ, Hedley D, Oza A, Siu LL, Pond GR, Moore MJ. Knox JJ, et al. Among authors: hedley d. Ann Oncol. 2004 May;15(5):770-4. doi: 10.1093/annonc/mdh172. Ann Oncol. 2004. PMID: 15111345 Free article. Clinical Trial.

4

Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer.

Townsley CA, Major P, Siu LL, Dancey J, Chen E, Pond GR, Nicklee T, Ho J, Hedley D, Tsao M, Moore MJ, Oza AM. Townsley CA, et al. Among authors: hedley d. Br J Cancer. 2006 Apr 24;94(8):1136-43. doi: 10.1038/sj.bjc.6603055. Br J Cancer. 2006. PMID: 16570047 Free PMC article. Clinical Trial.

5

A phase II study of temozolomide in advanced untreated pancreatic cancer.

Moore MJ, Feld R, Hedley D, Oza A, Siu LL. Moore MJ, et al. Among authors: hedley d. Invest New Drugs. 1998;16(1):77-9. doi: 10.1023/a:1006043332368. Invest New Drugs. 1998. PMID: 9740547 Clinical Trial.

6

Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice.

Ng SS, Tsao MS, Nicklee T, Hedley DW. Ng SS, et al. Among authors: hedley dw. Clin Cancer Res. 2001 Oct;7(10):3269-75. Clin Cancer Res. 2001. PMID: 11595724

7

A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer.

Mackay H, Hedley D, Major P, Townsley C, Mackenzie M, Vincent M, Degendorfer P, Tsao MS, Nicklee T, Birle D, Wright J, Siu L, Moore M, Oza A. Mackay H, et al. Among authors: hedley d. Clin Cancer Res. 2005 Aug 1;11(15):5526-33. doi: 10.1158/1078-0432.CCR-05-0081. Clin Cancer Res. 2005. PMID: 16061869 Clinical Trial.

8

A Phase 2 study of perifosine in advanced or metastatic breast cancer.

Leighl NB, Dent S, Clemons M, Vandenberg TA, Tozer R, Warr DG, Crump RM, Hedley D, Pond GR, Dancey JE, Moore MJ. Leighl NB, et al. Among authors: hedley d. Breast Cancer Res Treat. 2008 Mar;108(1):87-92. doi: 10.1007/s10549-007-9584-x. Epub 2007 Apr 26. Breast Cancer Res Treat. 2008. PMID: 17458693 Clinical Trial.

9

Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma.

Ng SS, Tsao MS, Nicklee T, Hedley DW. Ng SS, et al. Mol Cancer Ther. 2002 Aug;1(10):777-83. Mol Cancer Ther. 2002. PMID: 12492110

10

Suppression of the hypoxia-inducible factor-1 response in cervical carcinoma xenografts by proteasome inhibitors.

Birle DC, Hedley DW. Birle DC, et al. Cancer Res. 2007 Feb 15;67(4):1735-43. doi: 10.1158/0008-5472.CAN-06-2722. Cancer Res. 2007. PMID: 17308115

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

402 results

Search Page